R. Subramanian

发表

Absorption, Distribution, Metabolism, Excretion (ADME), Drug-drug interaction potential and Prediction of Human Pharmacokinetics of SUVN-G3031, a Novel Histamine 3 Receptor (H3R) inverse agonist in Clinical development for the treatment of Narcolepsy.

Abdul Rasheed Mohammed, R. Nirogi, G. Bhyrapuneni, 2020, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study

R. Nirogi, J. Cummings, A. Shinde, 2022, Neurology and Therapy.

Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H3 Receptor Inverse Agonist with Robust Wake-Promoting Activity.

Abdul Rasheed Mohammed, R. Nirogi, A. Shinde, 2019, Journal of medicinal chemistry.

Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study

R. Nirogi, J. Cummings, A. Shinde, 2022, Neurology and Therapy.

Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation

R. Nirogi, G. Bhyrapuneni, N. Muddana, 2021, Psychopharmacology.

Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane hydrochloride (SUVN-911): A Novel, Potent, Selective and Orally Active Neuronal Nicotinic Acetylcholine α4β2 Receptor Antagonist for the Treatment of Depression.

Abdul Rasheed Mohammed, R. Nirogi, G. Bhyrapuneni, 2020, Journal of medicinal chemistry.

Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease.

Abdul Rasheed Mohammed, R. Nirogi, G. Bhyrapuneni, 2015, European journal of medicinal chemistry.

Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization

Abdul Rasheed Mohammed, R. Nirogi, R. Subramanian, 2022, Psychopharmacology.

1‐[2‐(1‐Cyclobutylpiperidin‐4‐yloxy)‐6,7‐dihydro‐4H‐thiazolo[5,4‐c]pyridin‐5‐yl]propan‐1‐one: a Histamine H3 Receptor Inverse Agonist with Efficacy in Animal Models of Cognition

Abdul Rasheed Mohammed, R. Nirogi, A. Shinde, 2021, ChemMedChem.

Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders

R. Nirogi, G. Bhyrapuneni, Arunkumar Manoharan, 2021, Journal of psychopharmacology.

SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization

R. Nirogi, G. Bhyrapuneni, N. Muddana, 2019, Behavioural pharmacology.

Benzamide derivatives and their constrained analogs as histamine H3 receptor antagonists.

Abdul Rasheed Mohammed, R. Nirogi, G. Bhyrapuneni, 2016, European journal of medicinal chemistry.

Design, synthesis, and pharmacological evaluation of piperidin-4-yl amino aryl sulfonamides: novel, potent, selective, orally active, and brain penetrant 5-HT₆ receptor antagonists.

R. Nirogi, M. Gampa, G. Bhyrapuneni, 2012, Journal of medicinal chemistry.

Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT6) Receptor Antagonist for Potential Treatment of Alzheimer's Disease.

Abdul Rasheed Mohammed, R. Nirogi, G. Bhyrapuneni, 2017, Journal of medicinal chemistry.

Age, Gender and Research Productivity: A Study of Speech and Hearing Faculty in India

Ramkumar Subramanian, Narayanasamy Nammalvar, R. Subramanian, 2017, J. Sci. Res..

Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT4 Receptor Partial Agonists.

Abdul Rasheed Mohammed, R. Nirogi, N. Muddana, 2018, Journal of medicinal chemistry.

Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4 Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's Disease.

Abdul Rasheed Mohammed, R. Nirogi, N. Muddana, 2021, Journal of medicinal chemistry.

Potential beneficial effects of masupirdine (SUVN‐502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses

Abdul Rasheed Mohammed, R. Nirogi, J. Cummings, 2022, International journal of geriatric psychiatry.

Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for the potential treatment of Alzheimer's disease: Behavioural, neurochemical and pharmacological profiling.

Abdul Rasheed Mohammed, R. Nirogi, R. Subramanian, 2023, European journal of pharmacology.

Suvn-g3031, an h3 receptor inverse agonist, produces procognitive effects without affecting sleep in preclinical models

R. Nirogi, Arunkumar Manoharan, A. Shinde, 2015, Alzheimer's & Dementia.